Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.
Cognition Therapeutics announces publication reviewing potential of zervimesine (CT1812) in dry AMD
One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom
Retinal biomarkers in OCT imaging may have predictive applications for nAMD
The authors evaluated shallow irregular pigment epithelial detachment, subretinal hyperreflective material, subretinal fluid, intraretinal fluid and other baseline OCT biomarkers
Italian study illuminates positive outcomes and common complications of SING IMT implantation
The implant was tested in eyes of patients with bilateral age-related macular degeneration who underwent cataract surgery
European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars
Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration
SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel
The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections
Apellis Pharmaceuticals receives Australian approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy
The approval of Syfovre makes it the first and only approved treatment for GA in Australia.